[logo] HealthTree Foundation
more_vert
close
person Sign In / Create Account

The Exciting Potential of CAR T Cells for Multiple Myeloma Treatment with a Carefully Designed Strategy to Boost Results and Mitigate Safety Concerns. Dr. Hermann Einsele, MD and Dr. Michael Hudecek, MD, University of Würzburg, Germany

The Exciting Potential of CAR T Cells for Multiple Myeloma Treatment with a Carefully Designed Strategy to Boost Results and Mitigate Safety Concerns. Dr. Hermann Einsele, MD and Dr. Michael Hudecek, MD, University of Würzburg, Germany image

The Exciting Potential of CAR T Cells for Multiple Myeloma Treatment with a Carefully Designed Strategy to Boost Results and Mitigate Safety Concerns. Dr. Hermann Einsele, MD and Dr. Michael Hudecek, MD, University of Würzburg, Germany

Podcast
event May 25, 2015 / 11:00AM MDT
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

CAR T cell therapies are an exceptionally exciting non-transplant therapy future option for blood cancer patients, including multiple myeloma. CAR T cells are an engineered product, so selecting the best one and engineering it in the best way is of critical importance. Drs. Einsele and Hudecek share their deep experience in the use of CAR T cells and the lessons learned to increase the effectivity while also boosting safety measures. They describe how T cells are removed from a blood sample, engingeered to target the CS1 protein found on myeloma cells, grown up and expanded and then given back to the patient. This is a non-transplant option that stays active in patients for years. Because some testing in leukemia has shown "immune escape" or a loss of the targeted protein in 5-10% of patients, Drs. Einsele and Hudecek have identified a companion target, BCMA, to give the immune system a second targeting option. Because CAR T cells are potentially curative but extremely powerful, they have also developed an emergency brake in case of any possible negative reaction in patients using a specific antibody. And because all CAR T cells are not the same (as they are engineered), they are using what has been already proven with the safety studies done in elotuzumab; the HuLuc63 targeting domain . The work shows a very thorough approach with much contingency planning, based on many years of immunotherapy research.  The Myeloma Crowd Radio Show with Dr. Hermann Einsele and Dr. Michael Hudecek. 

Takeda-5x3-towel-logo

Schedule & Agenda

Event panelist Dr. Hermann Einsele, MD and Dr. Michael Hudecek, MD and Jenny Ahlstrom
11:00 AM
Discussion
Dr. Hermann Einsele, MD and Dr. Michael Hudecek, MD and Jenny Ahlstrom

Speakers & Moderators

The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Thanks to our sponsors:
Johnson and Johnson logo
Sanofi logo
Pfizer logo
GSK logo
Regeneron logo
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Blood Cancer Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.